Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt to Equity (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Debt to Equity for 5 consecutive years, with -$1.13 as the latest value for Q2 2022.

  • On a quarterly basis, Debt to Equity rose 10.96% to -$1.13 in Q2 2022 year-over-year; TTM through Jun 2022 was -$1.13, a 10.96% increase, with the full-year FY2020 number at -$1.29, down 26.13% from a year prior.
  • Debt to Equity was -$1.13 for Q2 2022 at Theravance Biopharma, down from -$1.12 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$1.02 in Q4 2019 to a low of -$4.45 in Q4 2018.
  • A 5-year average of -$1.66 and a median of -$1.28 in 2020 define the central range for Debt to Equity.
  • Peak YoY movement for Debt to Equity: skyrocketed 76.99% in 2019, then dropped 26.13% in 2020.
  • Theravance Biopharma's Debt to Equity stood at -$4.45 in 2018, then surged by 76.99% to -$1.02 in 2019, then fell by 26.13% to -$1.29 in 2020, then rose by 7.11% to -$1.2 in 2021, then grew by 5.58% to -$1.13 in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Debt to Equity are -$1.13 (Q2 2022), -$1.12 (Q1 2022), and -$1.2 (Q3 2021).